Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia.

Nature cell biology - 1 Nov 2020

Saliakoura Maria, Rossi Sebastiano Matteo, Pozzato Chiara, Heidel Florian H, Schnöder Tina M, Savic Prince Spasenija, Bubendorf Lukas, Pinton Paolo, A Schmid Ralph, Baumgartner Johanna, Freigang Stefan, Berezowska Sabina A, Rimessi Alessandro, Konstantinidou Georgia

Abstract excerpt

Mutant KRAS modulates the metabolic plasticity of cancer cells to confer a growth advantage during hypoxia, but the molecular underpinnings are largely unknown. Using a lipidomic screen, we found that PLCγ1 is suppressed during hypoxia in KRAS-mutant human lung adenocarcinoma cancer cell lines. Suppression of PLCγ1 in hypoxia promotes a less oxidative cancer cell metabolism state, reduces the formation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Energy Metabolism

Share to Lipid Peroxidation

Share to Mice, Inbred NOD

Share to Phospholipase C gamma

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 33077911
DOI: 10.1038/s41556-020-00592-8
PMCID: PMC7610419

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia.PMID 33077911Read ↗

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancerSemantic proximity Read ↗

The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications.Semantic proximity Read ↗

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy.Semantic proximity Read ↗

Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Semantic proximity Read ↗

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.Semantic proximity Read ↗

Shining a light on metabolic vulnerabilities in non-small cell lung cancer.Semantic proximity Read ↗

ATM functions as a rheostat of metabolic stress in small-cell lung cancerSemantic proximity Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

Oncogene-Driven Metabolic Alterations in CancerSemantic proximity Read ↗

Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery.Semantic proximity Read ↗

Mitochondrial metabolism as a potential novel therapeutic target for lung adenocarcinomaSemantic proximity Read ↗

DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.